Welcome to LookChem.com Sign In|Join Free
  • or
5-Pyridin-4-yl-4H-[1,2,4]triazole-3-thiol is a chemical compound that is primarily recognized for its role in chemical research due to its distinctive molecular structure. It features a triazole ring, which is a five-membered aromatic ring with two nitrogen atoms, coupled with a pyridinyl functional group (a basic aromatic ring with one nitrogen atom) and a thiol group (an organosulfur compound that contains a carbon-bonded sulfhydryl). 5-PYRIDIN-4-YL-4H-[1,2,4]TRIAZOLE-3-THIOL's unique structural properties make it valuable for various applications in chemical and pharmaceutical research. However, details such as its physical and chemical properties, toxicity, and safety measures for handling and storage are not widely documented and depend largely on specifics of its synthesis and applications.

1477-24-3

Post Buying Request

1477-24-3 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1477-24-3 Usage

Uses

Used in Chemical Research:
5-Pyridin-4-yl-4H-[1,2,4]triazole-3-thiol is used as a research compound for its unique molecular structure, which includes a triazole ring, a pyridinyl functional group, and a thiol group. Its properties make it valuable for studying chemical reactions and interactions in various research settings.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 5-Pyridin-4-yl-4H-[1,2,4]triazole-3-thiol is used as a potential lead compound for the development of new drugs. Its structural features may offer opportunities for the creation of novel therapeutic agents, particularly in the areas of medicinal chemistry and drug design.
Used in Material Science:
5-Pyridin-4-yl-4H-[1,2,4]triazole-3-thiol may also be used in material science applications, where its chemical properties could contribute to the development of new materials with specific characteristics, such as improved stability or reactivity.

Check Digit Verification of cas no

The CAS Registry Mumber 1477-24-3 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,4,7 and 7 respectively; the second part has 2 digits, 2 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1477-24:
(6*1)+(5*4)+(4*7)+(3*7)+(2*2)+(1*4)=83
83 % 10 = 3
So 1477-24-3 is a valid CAS Registry Number.
InChI:InChI=1/C7H6N4S/c12-7-9-6(10-11-7)5-1-3-8-4-2-5/h1-4H,(H2,9,10,11,12)

1477-24-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name 1H-1,2,4-Triazole-3-thiol, 5-(4-pyridyl)-

1.2 Other means of identification

Product number -
Other names 5-(4-Pyridyl)-3-mercapto-1H-1,2,4-triazole

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1477-24-3 SDS

1477-24-3Synthetic route

isoniazid
54-85-3

isoniazid

thiourea
17356-08-0

thiourea

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione
1477-24-3

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione

Conditions
ConditionsYield
Stage #1: isoniazid; thiourea at 170℃;
Stage #2: With sodium hydroxide
93.6%
N'-[1-Amino-1-pyridin-4-yl-meth-(Z)-ylidene]-hydrazinecarbodithioic acid methyl ester

N'-[1-Amino-1-pyridin-4-yl-meth-(Z)-ylidene]-hydrazinecarbodithioic acid methyl ester

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione
1477-24-3

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione

Conditions
ConditionsYield
With potassium hydroxide In methanol for 4h; Heating;85%
2-(pyridin-4-ylcarbonyl)hydrazinecarbothioamide
14397-24-1

2-(pyridin-4-ylcarbonyl)hydrazinecarbothioamide

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione
1477-24-3

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione

Conditions
ConditionsYield
With sodium hydroxide at 150℃; for 0.05h; Microwave irradiation;76%
Stage #1: 2-(pyridin-4-ylcarbonyl)hydrazinecarbothioamide With sodium hydroxide for 3h; Reflux;
Stage #2: With acetic acid
C13H13N5S

C13H13N5S

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione
1477-24-3

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione

Conditions
ConditionsYield
In butan-1-ol for 6h; Heating;40%
tetralin
119-64-2

tetralin

2-(pyridin-4-ylcarbonyl)hydrazinecarbothioamide
14397-24-1

2-(pyridin-4-ylcarbonyl)hydrazinecarbothioamide

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione
1477-24-3

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione

2-(pyridin-4-ylcarbonyl)hydrazinecarbothioamide
14397-24-1

2-(pyridin-4-ylcarbonyl)hydrazinecarbothioamide

ethanol
64-17-5

ethanol

sodium ethanolate
141-52-6

sodium ethanolate

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione
1477-24-3

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione

isonicotinic acid hydrazide; thiocyanate

isonicotinic acid hydrazide; thiocyanate

A

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione
1477-24-3

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione

B

2-(pyridin-4-ylcarbonyl)hydrazinecarbothioamide
14397-24-1

2-(pyridin-4-ylcarbonyl)hydrazinecarbothioamide

Conditions
ConditionsYield
at 140 - 150℃;
C14H15N5S

C14H15N5S

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione
1477-24-3

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione

Conditions
ConditionsYield
In butan-1-ol for 6h; Heating;
N-phenyl-4-pyridinecarbohydrazonamide

N-phenyl-4-pyridinecarbohydrazonamide

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione
1477-24-3

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 75 percent / aq. HCl / 12 h
2: 40 percent / butan-1-ol / 6 h / Heating
View Scheme
C13H14N4

C13H14N4

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione
1477-24-3

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 75 percent / aq. HCl / 12 h
2: butan-1-ol / 6 h / Heating
View Scheme
pyridine-4-carboxylic acid
55-22-1

pyridine-4-carboxylic acid

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione
1477-24-3

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: oxalyl dichloride / N,N-dimethyl-formamide; dichloromethane / 2.5 h / 0 - 20 °C
2: tetrahydrofuran / 1.5 h / 0 - 20 °C
3: sodium hydroxide / 0.05 h / 150 °C / Microwave irradiation
View Scheme
4-(chlorocarbonyl)pyridine
14254-57-0

4-(chlorocarbonyl)pyridine

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione
1477-24-3

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: tetrahydrofuran / 1.5 h / 0 - 20 °C
2: sodium hydroxide / 0.05 h / 150 °C / Microwave irradiation
View Scheme
isoniazid
54-85-3

isoniazid

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione
1477-24-3

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: potassium hydroxide / ethanol / 10 h / Reflux
2: ammonium hydroxide / 10 h / Reflux
View Scheme
Multi-step reaction with 2 steps
1: hydrogenchloride / 3 h / Reflux
2: sodium hydroxide / 3 h / Reflux
View Scheme
4-pyridinecarboxylic acid, methyl ester
2459-09-8

4-pyridinecarboxylic acid, methyl ester

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione
1477-24-3

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: hydrazine hydrate / ethanol / 5 h / Reflux
2: potassium hydroxide / ethanol / 10 h / Reflux
3: ammonium hydroxide / 10 h / Reflux
View Scheme
potassium 4-pyridinyldithiocarbazate
61019-32-7

potassium 4-pyridinyldithiocarbazate

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione
1477-24-3

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione

Conditions
ConditionsYield
With ammonium hydroxide for 10h; Reflux;
3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione
1477-24-3

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione

ethyl 2-chloro-3-oxo-butyrate
609-15-4

ethyl 2-chloro-3-oxo-butyrate

ethyl 6-methyl-2-(pyridin-4-yl)thiazolo[3,2-b][1,2,4]triazole-5-carboxylate

ethyl 6-methyl-2-(pyridin-4-yl)thiazolo[3,2-b][1,2,4]triazole-5-carboxylate

Conditions
ConditionsYield
Stage #1: 3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione; ethyl 2-chloro-3-oxo-butyrate In ethanol Reflux;
Stage #2: With sulfuric acid In ethanol Reflux;
89%
3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione
1477-24-3

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione

3-chloropentane-2,4-dione
1694-29-7

3-chloropentane-2,4-dione

1-(6-methyl-(2-(pyridin-4-yl)thiazolo[3,2-b][1,2,4]triazol-5-yl))ethanone

1-(6-methyl-(2-(pyridin-4-yl)thiazolo[3,2-b][1,2,4]triazol-5-yl))ethanone

Conditions
ConditionsYield
Stage #1: 3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione; 3-chloropentane-2,4-dione In ethanol Reflux;
Stage #2: With sulfuric acid In ethanol Reflux;
78%
3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione
1477-24-3

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione

[tris(triphenylphosphine) ruthenium(III) trichloride]
30050-39-6, 23311-38-8

[tris(triphenylphosphine) ruthenium(III) trichloride]

C7H5N4S(1-)*2Cl(1-)*Ru(3+)*2C18H15P

C7H5N4S(1-)*2Cl(1-)*Ru(3+)*2C18H15P

Conditions
ConditionsYield
In benzene Reflux;76%
3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione
1477-24-3

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione

trichlorotris(triphenylarsine)ruthenium(III)
61769-11-7, 52620-83-4, 72747-39-8

trichlorotris(triphenylarsine)ruthenium(III)

C7H5N4S(1-)*2Cl(1-)*Ru(3+)*2C18H15As

C7H5N4S(1-)*2Cl(1-)*Ru(3+)*2C18H15As

Conditions
ConditionsYield
In benzene Reflux;76%
3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione
1477-24-3

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione

[RuBr3(PPh3)3]
118519-70-3

[RuBr3(PPh3)3]

C7H5N4S(1-)*2Br(1-)*Ru(3+)*2C18H15P

C7H5N4S(1-)*2Br(1-)*Ru(3+)*2C18H15P

Conditions
ConditionsYield
In benzene Reflux;76%
3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione
1477-24-3

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione

[tris(triphenylarsine) ruthenium(III) tribromide]
63632-06-4, 72747-40-1

[tris(triphenylarsine) ruthenium(III) tribromide]

C7H5N4S(1-)*2Br(1-)*Ru(3+)*2C18H15As

C7H5N4S(1-)*2Br(1-)*Ru(3+)*2C18H15As

Conditions
ConditionsYield
In benzene Reflux;76%
3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione
1477-24-3

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione

ethyl (2-chloroaceto)acetate
638-07-3

ethyl (2-chloroaceto)acetate

ethyl 2-(2-(pyridin-4-yl)thiazolo[3,2-b][1,2,4]triazol-6-yl)acetate

ethyl 2-(2-(pyridin-4-yl)thiazolo[3,2-b][1,2,4]triazol-6-yl)acetate

Conditions
ConditionsYield
Stage #1: 3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione; ethyl (2-chloroaceto)acetate In ethanol Reflux;
Stage #2: With sulfuric acid In ethanol Reflux;
69%
3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione
1477-24-3

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione

ethyl Bromopyruvate
70-23-5

ethyl Bromopyruvate

ethyl 2-(pyridin-4-yl)thiazolo[3,2-b][1,2,4]triazole-6-carboxylate

ethyl 2-(pyridin-4-yl)thiazolo[3,2-b][1,2,4]triazole-6-carboxylate

Conditions
ConditionsYield
Stage #1: 3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione; ethyl Bromopyruvate In ethanol Reflux;
Stage #2: With sulfuric acid In ethanol Reflux;
68%
3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione
1477-24-3

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione

α-bromoacetophenone
70-11-1

α-bromoacetophenone

1-phenyl-2-((3-(pyridin-4-yl)-1,2,4-triazol-5-yl)thio)ethanone

1-phenyl-2-((3-(pyridin-4-yl)-1,2,4-triazol-5-yl)thio)ethanone

Conditions
ConditionsYield
With sodium acetate In methanol; N,N-dimethyl-formamide at 20℃; for 120h;67%
3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione
1477-24-3

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione

α-bromoacetophenone
70-11-1

α-bromoacetophenone

6-phenyl-2(pyridin-4-yl)thiazolo[3,2-b][1,2,4]triazole

6-phenyl-2(pyridin-4-yl)thiazolo[3,2-b][1,2,4]triazole

Conditions
ConditionsYield
Stage #1: 3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione; α-bromoacetophenone In ethanol Reflux;
Stage #2: With sulfuric acid In ethanol Reflux;
67%
3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione
1477-24-3

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione

ethyl 2-chloro-3-oxo-butyrate
609-15-4

ethyl 2-chloro-3-oxo-butyrate

ethyl 3-oxo-2-((3-(pyridin-4-yl)-1,2,4-triazol-5-yl)thio)butanoate

ethyl 3-oxo-2-((3-(pyridin-4-yl)-1,2,4-triazol-5-yl)thio)butanoate

Conditions
ConditionsYield
With sodium acetate In methanol; N,N-dimethyl-formamide at 20℃; for 168h;65%
3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione
1477-24-3

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione

3-chloropentane-2,4-dione
1694-29-7

3-chloropentane-2,4-dione

3-((3-(pyridin-4-yl)-1,2,4-triazol-5-yl)thio)pentane-2,4-dione

3-((3-(pyridin-4-yl)-1,2,4-triazol-5-yl)thio)pentane-2,4-dione

Conditions
ConditionsYield
With sodium acetate In methanol; N,N-dimethyl-formamide at 20℃; for 168h;62%
3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione
1477-24-3

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione

2-bromo-N-(2-(2-(4-ethylphenylamino)-2-oxoethylthio)benzo[d]thiazol-6-yl)acetamide

2-bromo-N-(2-(2-(4-ethylphenylamino)-2-oxoethylthio)benzo[d]thiazol-6-yl)acetamide

N-(4-ethylphenyl)-2-(6-(2-(5-(pyridin-4-yl)-4H-1,2,4-triazol-3-ylthio)acetamido)benzo[d]thiazol-2-ylthio)acetamide

N-(4-ethylphenyl)-2-(6-(2-(5-(pyridin-4-yl)-4H-1,2,4-triazol-3-ylthio)acetamido)benzo[d]thiazol-2-ylthio)acetamide

Conditions
ConditionsYield
With potassium hydroxide In ethanol; water at 20℃; for 2h; regioselective reaction;61%
3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione
1477-24-3

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione

chloroacetone
78-95-5

chloroacetone

1-((3-(pyridin-4-yl)-1,2,4-triazol-5-yl)thio)propan-2-one

1-((3-(pyridin-4-yl)-1,2,4-triazol-5-yl)thio)propan-2-one

Conditions
ConditionsYield
With sodium acetate In methanol; N,N-dimethyl-formamide at 20℃; for 168h;57%
3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione
1477-24-3

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione

ethyl Bromopyruvate
70-23-5

ethyl Bromopyruvate

ethyl 2-oxo-3-((3-(pyridin-4-yl)-1,2,4-triazol-5-yl)thio)propanoate

ethyl 2-oxo-3-((3-(pyridin-4-yl)-1,2,4-triazol-5-yl)thio)propanoate

Conditions
ConditionsYield
With sodium acetate In methanol; N,N-dimethyl-formamide at 20℃; for 72h;57%
3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione
1477-24-3

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione

chloroacetone
78-95-5

chloroacetone

6-methyl-2-(pyridin-4-yl)thiazolo[3,2-b][1,2,4]triazole

6-methyl-2-(pyridin-4-yl)thiazolo[3,2-b][1,2,4]triazole

Conditions
ConditionsYield
Stage #1: 3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione; chloroacetone In ethanol Reflux;
Stage #2: With sulfuric acid In ethanol Reflux;
56%
3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione
1477-24-3

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione

1,3-Dichloroacetone
534-07-6

1,3-Dichloroacetone

6-chloromethyl-2-(pyridin-4-yl)thiazolo[3,2-b][1,2,4]triazole

6-chloromethyl-2-(pyridin-4-yl)thiazolo[3,2-b][1,2,4]triazole

Conditions
ConditionsYield
Stage #1: 3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione; 1,3-Dichloroacetone In ethanol Reflux;
Stage #2: With sulfuric acid In ethanol Reflux;
56%
3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione
1477-24-3

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione

ethyl (2-chloroaceto)acetate
638-07-3

ethyl (2-chloroaceto)acetate

ethyl 3-oxo-4-((3-(pyridin-4-yl)-1,2,4-triazol-5-yl)thio)butanoate

ethyl 3-oxo-4-((3-(pyridin-4-yl)-1,2,4-triazol-5-yl)thio)butanoate

Conditions
ConditionsYield
With sodium acetate In methanol; N,N-dimethyl-formamide at 20℃; for 168h;54%
3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione
1477-24-3

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione

1,3-Dichloroacetone
534-07-6

1,3-Dichloroacetone

1-chloro-3-((3-(pyridin-4-yl)-1,2,4-triazol-5-yl)thio)propan-2-one

1-chloro-3-((3-(pyridin-4-yl)-1,2,4-triazol-5-yl)thio)propan-2-one

Conditions
ConditionsYield
With sodium acetate In methanol; N,N-dimethyl-formamide at 20℃; for 48h;50%
3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione
1477-24-3

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione

1,3-Dichloro-2-propanol
96-23-1

1,3-Dichloro-2-propanol

2-Pyridin-4-yl-6,7-dihydro-5H-[1,2,4]triazolo[5,1-b][1,3]thiazin-6-ol
146198-13-2

2-Pyridin-4-yl-6,7-dihydro-5H-[1,2,4]triazolo[5,1-b][1,3]thiazin-6-ol

Conditions
ConditionsYield
With potassium hydroxide In methanol for 24h; Ambient temperature;31%
3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione
1477-24-3

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione

epichlorohydrin
106-89-8

epichlorohydrin

2-Pyridin-4-yl-6,7-dihydro-5H-[1,2,4]triazolo[5,1-b][1,3]thiazin-6-ol
146198-13-2

2-Pyridin-4-yl-6,7-dihydro-5H-[1,2,4]triazolo[5,1-b][1,3]thiazin-6-ol

Conditions
ConditionsYield
With potassium hydroxide In methanol for 24h; Ambient temperature;31%
3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione
1477-24-3

3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione

(2-chloroethyl)dimethylamine hydrochloride
4584-46-7

(2-chloroethyl)dimethylamine hydrochloride

N,N-dimethyl-2-<5'-(pyridin-4''-yl)-1',2',4'-triazol-3'-ylthio>ethylamine
88317-52-6

N,N-dimethyl-2-<5'-(pyridin-4''-yl)-1',2',4'-triazol-3'-ylthio>ethylamine

Conditions
ConditionsYield
With sodium methylate In ethanol for 4h; Heating;

1477-24-3Relevant academic research and scientific papers

Synthesis and Intramolecular Heterocyclization of Selected Isonicotinic Acid Thiocarbazides

Nurkenov,Karipova, G. Zh.,Seilkhanov,Satpaeva, Zh. B.,Fazylov,Nukhuly

, p. 1923 - 1926 (2019)

The reaction of isonicotinic acid hydrazide with ethyl-, allyl-, and cinnamoyl isothiocyanates has afforded the corresponding alkylthiosemicarbazides and the products of their intramolecular heterocyclization, 1,2,4-triazoles.

Heterocycles 39. Synthesis, characterization and evaluation of the anti-inflammatory activity of thiazolo[3,2-b][1,2,4]triazole derivatives bearing pyridin-3/4-yl moiety

Toma, Alexandra,Mogo?an, Cristina,Vlase, Laurian,Leonte, Denisa,Zaharia, Valentin

, p. 2602 - 2613 (2017)

Abstract: A series of pyridin-3/4-yl-thiazolo[3,2-b][1,2,4]triazole derivatives (5a–g, 6a–g) were synthesised by Hantzsch condensation of 5-pyridin-3/4-yl-1,2,4-triazole-3-thiol and diverse α-halocarbonyl compounds. Different reaction conditions (pH, temperature, solvent) were investigated for the efficient obtention of the target compounds. Under reflux and acidic conditions, the Hantzsch condensation was a one-step reaction. At room temperature and under basic conditions, it was possible to isolate the iminothioether intermediates 3/4a–g. These intermediates were cyclized in a subsequent step by treatment with concentrated sulphuric acid. The obtained compounds were evaluated for their anti-inflammatory activity. Three synthesised pyridyl-thiazolo[3,2-b][1,2,4]triazole derivatives (6c, 6d, 6f) were found to be good anti-inflammatory agents. Graphical Abstract: [InlineMediaObject not available: see fulltext.].

Reactivity of N1-dithioester substituted pyridinand pyrazincarboxamidrazones

Orlewska, Czeslawa,Pancechowska-Ksepko, Danuta,Foks, Henryk,Zwolska, Zofia,Augustynowicz-Kopec, Ewa

, p. 737 - 744 (2006)

The N1-dithioester substituted pyridin- and pyrazincarboxamidrazones underwent cyclocondensation to 5-methylsulfanyl-1,3,4- thiadiazole or 1,2,4-triazole derivatives, depending on the reaction conditions. With an excess of secondary amines, pyrazincarboxamidrazone dithioester gave 5-amino-1,3,4-thiadiazoles and with an ethanoloamine a 1,2,4-triazole derivative. Prepared compounds were evaluated as potential tuberculostatic agents, but the minimum inhibitory concentrations values indicated no significant activity. Copyright Taylor & Francis Group, LLC.

Synthesis, biological evaluation, and molecular modeling studies of acetophenones-tethered 1,2,4-triazoles and their oximes as epidermal growth factor receptor inhibitors

Abdel-Rahman, Hamdy M.,Ali, Ahmed M.,El-Wahab, Hend A. A. Abd,Qayed, Wesam S.

, (2021/11/27)

A series of 5-(4-pyridyl)-1,2,4-triazoles hybrids with acetophenones and their oxime derivatives was rationally designed and synthesized as epidermal growth factor receptor (EGFR) kinase inhibitors. Initially, drug Likeness and pharmacokinetics properties of the prepared compounds were evaluated. Afterward, the prepared compounds were in vitro screened for their ability to inhibit the growth of the NCI-60 human cancer cell lines where certain compounds showed moderate activity. Compounds 4e and 5b emerged as the most potent compounds in this series were further tested for their EGFR enzyme inhibition activity. They showed IC50 values of 0.14 and 0.18?μM, respectively, in comparison with Gefitinib as a reference with an IC50 value of 0.06?μM. Docking of compounds 4e and 5b into the binding site of EGFR tyrosine kinase was performed to explains their possible binding mode and to compare it with known inhibitors. Moreover, molecular dynamic simulations were estimated for deeper understanding of the binding mode of compounds 4e and 5b at the binding site of EGFR tyrosine kinase. The findings indicated that the novel ligands 4e and 5b were stable in the EGFR tyrosine kinase active site.

Structure-activity relationships of triazole-benzodioxine inhibitors of cathepsin X

Fonovi?, Ur?a Pe?ar,Gobec, Stanislav,Hrast, Martina,Knez, Damijan,Kos, Janko,Proj, Matic,Zidar, Nace

, (2020/03/24)

Cathepsin X is a cysteine carboxypeptidase that is involved in various physiological and pathological processes. In particular, highly elevated expression and activity of cathepsin X has been observed in cancers and neurodegenerative diseases. Previously, we identified compound Z9 (1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-((4-isopropyl-4H-1,2,4-triazol-3-yl)thio)ethan-1-one) as a potent and specific reversible cathepsin X inhibitor. Here, we have explored the effects of chemical variations to Z9 of either benzodioxine or triazol moieties, and the importance of the central ketomethylenethio linker. The ketomethylenethio linker was crucial for cathepsin X inhibition, whereas changes of the triazole heterocycle did not alter the inhibitory potencies to a greater extent. Replacement of benzodioxine moiety with substituted benzenes reduced cathepsin X inhibition. Overall, several synthesized compounds showed similar or improved inhibitory potencies against cathepsin X compared to Z9, with IC50 values of 7.1 μM–13.6 μM. Additionally, 25 inhibited prostate cancer cell migration by 21%, which is under the control of cathepsin X.

Synthesis, characterization of 1,2,4-triazole Schiff base derived 3d-metal complexes: Induces cytotoxicity in HepG2, MCF-7 cell line, BSA binding fluorescence and DFT study

Tyagi, Prateek,Tyagi, Monika,Agrawal, Swati,Chandra, Sulekh,Ojha, Himanshu,Pathak, Mallika

, p. 246 - 257 (2016/08/23)

Two novel Schiff base ligands H2L1 and H2L2 have been synthesized by condensation reaction of amine derivative of 1,2,4-triazole moiety with 2-hydroxy-4-methoxybenzaldehyde. Co(II), Ni(II), Cu(II) and Zn(II) of the synthesized Schiff bases were prepared by using a molar ratio of ligand:metal as 1:1. The structure of the Schiff bases and synthesized metal complexes were established by 1H NMR, UV–Vis, IR, Mass spectrometry and molar conductivity. The thermal stability of the complexes was study by TGA. Fluorescence quenching mechanism of metal complexes 1–4 show that Zn(II) and Cu(II) complex binds more strongly to BSA. In DFT studies the geometries of Schiff bases and metal complexes were fully optimized with respect to the energy using the 6-31?+?g(d,p) basis set. The spectral data shows that the ligands behaves as binegative tridentate. On the basis of the spectral studies, TGA and DFT data an octahedral geometry has been assigned for Co(II), Ni(II), square planar for Cu(II) and tetrahedral for Zn(II) complexes. The anticancer activity were screened against human breast cancer cell line (MCF-7) and human hepatocellular liver carcinoma cell line (Hep-G2). Result indicates that metal complexes shows increase cytotoxicity in proliferation to cell lines as compared to free ligand.

Synthesis and biological evaluation of 1,2,4-triazole-3-thione and 1,3,4-oxadiazole-2-thione as antimycobacterial agents

Sonawane, Amol D.,Rode, Navnath D.,Nawale, Laxman,Joshi, Rohini R.,Joshi, Ramesh A.,Likhite, Anjali P.,Sarkar, Dhiman

, p. 200 - 209 (2017/07/13)

Resistance among dormant mycobacteria leading to multidrug-resistant and extremely drug-resistant tuberculosis is one of the major threats. Hence, a series of 1,2,4-triazole-3-thione and 1,3,4-oxadiazole-2-thione derivatives (4a–5c) have been synthesized and screened for their antitubercular activity against Mycobacterium tuberculosis H37Ra (H37Ra). The triazolethiones 4b and 4v showed high antitubercular activity (both MIC and IC50) against the dormant H37Ra by in vitro and ex vivo. They were shown to have more specificity toward mycobacteria than other Gram-negative and Gram-positive pathogenic bacteria. The cytotoxicity was almost insignificant up to 100?μg/ml against THP-1, A549, and PANC-1 human cancer cell lines, and solubility was high in aqueous solution, indicating the potential of developing these compounds further as novel therapeutics against tuberculosis infection.

Design, Synthesis, and Evaluation of the Highly Selective and Potent G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor for the Potential Treatment of Heart Failure

Okawa, Tomohiro,Aramaki, Yoshio,Yamamoto, Mitsuo,Kobayashi, Toshitake,Fukumoto, Shoji,Toyoda, Yukio,Henta, Tsutomu,Hata, Akito,Ikeda, Shota,Kaneko, Manami,Hoffman, Isaac D.,Sang, Bi-Ching,Zou, Hua,Kawamoto, Tetsuji

, p. 6942 - 6990 (2017/09/07)

A novel class of therapeutic drug candidates for heart failure, highly potent and selective GRK2 inhibitors, exhibit potentiation of β-adrenergic signaling in vitro studies. Hydrazone derivative 5 and 1,2,4-triazole derivative 24a were identified as hit compounds by HTS. New scaffold generation and SAR studies of all parts resulted in a 4-methyl-1,2,4-triazole derivative with an N-benzylcarboxamide moiety with highly potent activity toward GRK2 and selectivity over other kinases. In terms of subtype selectivity, these compounds showed enough selectivity against GRK1, 5, 6, and 7 with almost equipotent inhibition to GRK3. Our medicinal chemistry efforts led to the discovery of 115h (GRK2 IC50 = 18 nM), which was obtained the cocrystal structure with human GRK2 and an inhibitor of GRK2 that potentiates β-adrenergic receptor (βAR)-mediated cAMP accumulation and prevents internalization of βARs in β2AR-expressing HEK293 cells treated with isoproterenol. Therefore, 115h appears to be a novel class of therapeutic for heart failure treatment.

Diaryl-Substituted Azolylthioacetamides: Inhibitor Discovery of New Delhi Metallo-β-Lactamase-1 (NDM-1)

Zhang, Yi-Lin,Yang, Ke-Wu,Zhou, Ya-Jun,LaCuran, Alecander E.,Oelschlaeger, Peter,Crowder, Michael W.

, p. 2445 - 2448 (2015/08/24)

The emergence and spread of antibiotic-resistant pathogens is a global public health problem. Metallo-β-lactamases (MβLs) such as New Delhi MβL-1 (NDM-1) are principle contributors to the emergence of resistance because of their ability to hydrolyze almost all known β-lactam antibiotics including penicillins, cephalosporins, and carbapenems. A clinical inhibitor of MBLs has not yet been found. In this study we developed eighteen new diaryl-substituted azolylthioacetamides and found all of them to be inhibitors of the MβL L1 from Stenotrophomonas maltophilia (KiiiII ion(s) preferentially via the triazole moiety, while other moieties interact mostly with the conserved active site residues Lys224 (CcrA, NDM-1, and ImiS) or Ser221 (L1).

Synthesis and invitro Evaluation of West Nile Virus Protease Inhibitors Based on the 2-{6-[2-(5-Phenyl-4H-{1,2,4]triazol-3-ylsulfanyl)acetylamino]benzothiazol-2-ylsulfanyl}acetamide Scaffold

Samanta, Sanjay,Lim, Ting Liang,Lam, Yulin

, p. 994 - 1001 (2013/07/27)

In recent years, clinical symptoms resulting from West Nile virus (WNV) infection have worsened in severity, with an increased frequency in neuroinvasive diseases among the elderly. As there are presently no successful therapies against WNV for use in humans, continual efforts to develop new chemotherapeutics against this virus are highly desired. The viral NS2B-NS3 protease is a promising target for viral inhibition due to its importance in viral replication and its unique substrate preference. In this study, a WNV NS2B-NS3 protease inhibitor with a 2-{6-[2-(5-phenyl-4H-[1,2,4]triazol-3-ylsulfanyl)acetylamino]benzothiazol-2-ylsulfanyl}acetamide scaffold was identified during screening. Optimization of this initial hit by synthesis and screening of a focused compound library with this scaffold led to the identification of a novel uncompetitive inhibitor (1a24, IC50=3.4±0.2μM) of the WNV NS2B-NS3 protease. Molecular docking of 1a24 into the WNV protease showed that the compound interferes with productive interactions of the NS2B cofactor with the NS3 protease and is an allosteric inhibitor of the WNV NS3 protease.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1477-24-3